BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence

Journal of Clinical Oncology

Volumn 32, Issue 25, 2014, Pages 2718-2726

  Xing, Mingzhao ^a   Liu, Rengyun ^a   Liu, Xiaoli ^a   Murugan, Avaniyapuram Kannan ^a   Zhu, Guangwu ^a   Zeiger, Martha A ^a   Pai, Sara ^a   Bishop, Justin ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; TELOMERASE REVERSE TRANSCRIPTASE; BRAF PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; THYROID PAPILLARY CARCINOMA; CARCINOMA; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; THYROID TUMOR; TUMOR RECURRENCE;

CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; TELOMERASE; THYROID NEOPLASMS;

EID: 84906815246     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.5094     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
2. Howlader N, Noone AM, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2010. Bethesda, MD, National Cancer Institute. http://seer.cancer.gov/csr/ 1975-2010/
3. Brown RL, de Souza JA, Cohen EE: Thyroid cancer: Burden of illness and management of disease. J Cancer 2:193-199, 2011
4. Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428, 1994
5. Tuttle RM, Ball DW, Byrd D, et al: Thyroid carcinoma. J Natl Compr Canc Netw 8:1228-1274, 2010
6. Xing M, Haugen BR, Schlumberger M: Progress in molecular-based management of differentiated thyroid cancer. Lancet 381:1058-1069, 2013
7. Xing M: Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 321:86-93, 2010
8. Kim TH, Park YJ, Lim JA, et al: The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: A metaanalysis. Cancer 118:1764-1773, 2012
9. Tufano RP, Teixeira GV, Bishop J, et al: BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: A systematic review and metaanalysis. Medicine (Baltimore) 91:274-286, 2012
10. Xing M: BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762, 2007
11. Xing M, Westra WH, Tufano RP, et al: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379, 2005
12. Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262, 2005
13. Xing M: Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 13:184-199, 2013
14. Liu X, Bishop J, Shan Y, et al: Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 20:603-610, 2013
15. Blasco MA: Telomeres and human disease: Ageing, cancer and beyond. Nat Rev Genet 6:611-622, 2005
16. Mocellin S, Pooley KA, Nitti D: Telomerase and the search for the end of cancer. Trends Mol Med 19:125-133, 2013
17. Smekalova EM, Shubernetskaya OS, Zvereva MI, et al: Telomerase RNA biosynthesis and processing. Biochemistry (Mosc) 77:1120-1128, 2012
18. Gonzalez-Suarez E, Flores JM, Blasco MA: Cooperation between p53 mutation and high telomerase transgenic expression in spontaneous cancer development. Mol Cell Biol 22:7291-7301, 2002
19. Gonzalez-Suarez E, Samper E, Ramirez A, et al: Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J 20:2619-2630, 2001
20. Capezzone M, Marchisotta S, Cantara S, et al: Telomeres and thyroid cancer. Curr Genomics 10: 526-533, 2009
21. Saji M, Xydas S, Westra WH, et al: Human telomerase reverse transcriptase (hTERT) gene expression in thyroid neoplasms. Clin Cancer Res 5:1483-1489, 1999
22. Horn S, Figl A, Rachakonda PS, et al: TERT promoter mutations in familial and sporadic melanoma. Science 339:959-961, 2013
23. Huang FW, Hodis E, Xu MJ, et al: Highly recurrent TERT promoter mutations in human melanoma. Science 339:957-959, 2013
24. Janknecht R, Ernst WH, Nordheim A: SAP1a is a nuclear target of signaling cascades involving ERKs. Oncogene 10:1209-1216, 1995
25. Strahl T, Gille H, Shaw PE: Selective response of ternary complex factor Sap1a to different mitogen-activated protein kinase subgroups. Proc Natl Acad Sci U S A 93:11563-11568, 1996
26. Whitmarsh AJ, Shore P, Sharrocks AD, et al: Integration of MAP kinase signal transduction pathways at the serum response element. Science 269:403-407, 1995
27. Vinagre J, Almeida A, Populo H, et al: Frequency of TERT promoter mutations in human cancers. Nat Commun 4:2185, 2013
28. Killela PJ, Reitman ZJ, Jiao Y, et al: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110:6021-6026, 2013
29. Kinde I, Munari E, Faraj SF, et al: TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res 73:7162-7167, 2013
30. Qu Y, Dang S, Wu K, et al: TERT promoter mutations predict worse survival in laryngeal cancer patients. Int J Cancer 10.1002/ijc.28728 [epub ahead of print on January 16, 2014]
31. Xing M, Alzahrani AS, Carson KA, et al: Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309:1493-1501, 2013
32. Landa I, Ganly I, Chan TA, et al: Frequent somatic TERT promoter mutations in thyroid cancer: Higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 98:E1562-E1566, 2013
33. Liu T, Wang N, Cao J, et al: The age-and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 10.1038/onc. 2013.446 [epub ahead of print on October 21, 2013]
34. van Staveren WC, Solis DW, Delys L, et al: Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype. Cancer Res 67:8113-8120, 2007
35. Liu D, Xing J, Trink B, et al: BRAF mutationselective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and geneticpotentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer 127:2965-2973, 2010
36. Liu R, Liu D, Trink E, et al: The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. J Clin Endocrinol Metab 96:E577-E585, 2011
37. Liu Z, Hou P, Ji M, et al: Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93:3106-3116, 2008
38. Liu X, Qu S, Liu R, et al: TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathologic characteristics of thyroid cancer. J Clin Endocrinol Metab 99:E1130-E1136, 2014